Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $95 to $94.
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $95 to $94.